Apyx Medical reports Renuvion study shows increased elastin, reduced inflammation at 180 days
Bitget2026/09/29 12:07- Apyx Medical disclosed results from a prospective clinical study of its Renuvion device, now published in a peer-reviewed journal.
- Results have already been presented via publication, not flagged for a future conference presentation.
- Biopsy findings supported improved skin quality signals, with reduced inflammation and favorable tissue remodeling, without safety signals tied to abnormal healing.
- Participants and physicians reported visible aesthetic improvement, with uniformly high satisfaction and recommendation intent.
- Data add human tissue evidence that could support broader procedural adoption and marketing claims for Renuvion in aesthetic surgery.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After acquiring SpotHero, Uber (UBER.US) makes its debut in the parking sector with a parking space reservation feature, initially available in 15 U.S. cities
Uber has launched a brand new parking space reservation feature, which marks its first step in the parking sector following its acquisition of the parking app SpotHero earlier this year.
Arbitrum will welcome a new propAMM
Domestic sales "underperform," PepsiCo (PEP.US) launches mass layoffs of thousands in North America
PepsiCo North America has cut about 1,000 jobs to streamline operations, as beverage sales in the third quarter fell by 2% year-on-year and the full-year profit outlook has been revised downward.
WLFI: Token buyback will be carried out on Aster through a public wallet
Crypto prices
More
